Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials

References

• Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell. 2006;127(4):679–10. doi:10.1016/j.cell.2006.11.001.
   PubMed Web of Science ®Google Scholar
• Moris D, Lu L, Qian S. Mechanisms of liver-induced tolerance. Curr Opin Organ Transplant. 2017;22(1):71–78. doi:10.1097/MOT.0000000000000380.
   PubMed Web of Science ®Google Scholar
• Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham K, Gladney WL, Hua X, et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature. 2019;567(7747):249–252. doi:10.1038/s41586-019-1004-y.
   PubMed Web of Science ®Google Scholar
• Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139(12):2679–2686. doi:10.1002/ijc.30400.
   PubMed Web of Science ®Google Scholar
• Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624–1633. doi:10.1002/()1097-0142.
   PubMed Web of Science ®Google Scholar
• Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78–84. doi:10.1016/j.lungcan.2014.07.020.
   PubMed Web of Science ®Google Scholar
• Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, HIZAWA N. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol. 2015;3(1):217–221. doi:10.3892/mco.2014.410.
   PubMedGoogle Scholar
• Nakazawa K, Kurishima K, Tamura T, Kagohashi K, Ishikawa H, Satoh H, HIZAWA N. Specific organ metastases and survival in small cell lung cancer. Oncol Lett. 2012;4(4):617–620. doi:10.3892/ol.2012.792.
   PubMed Web of Science ®Google Scholar
• Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34(14):1652–1659. doi:10.1200/JCO.2015.65.7270.
   PubMed Web of Science ®Google Scholar
• Dong F, Shen Y, Gao F, Xu T, Wang X, Zhang X, Zhong S, Zhang M, Chen S, Shen Z, et al. Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study. Cancer Manage Res. 2017;9:611–626. doi:10.2147/CMAR.
   PubMed Web of Science ®Google Scholar
• Kouri BE, Abrams RA, Al-Refaie WB, Azad N, Farrell J, Gaba RC, Gervais DA, Gipson MG, Kolbeck KJ, Marshalleck FE, et al. ACR appropriateness criteria radiologic management of hepatic malignancy. J Am Coll Radiol. 2016;13(3):265–273. doi:10.1016/j.jacr.2015.12.001.
   PubMed Web of Science ®Google Scholar
• Akgül Ö, Çetinkaya E, Ersöz Ş, Tez M. Role of surgery in colorectal cancer liver metastases. World J Gastroenterol. 2014;20(20):6113–6122. doi:10.3748/wjg.v20.i20.6113.
   PubMed Web of Science ®Google Scholar
• Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, Jaeck D, Saric J, Le Treut YP, Belghiti J, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244(4):524–535. doi:10.1097/01.sla.0000239036.46827.5f.
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Okumura N, Ohata K, Igai H, Matsuoka T, Kameyama K. Postrecurrence survival in patients with stage I non-small cell lung cancer. Eur Jcardio-thoracic Surg. 2008;34(3):499–504. doi:10.1016/j.ejcts.2008.05.016.
   PubMed Web of Science ®Google Scholar
• Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–3391. doi:10.1172/JCI80011.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034. doi:10.1084/jem.192.7.1027.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J. 1992;11(11):3887–3895. doi:10.1002/embj.1992.11.issue-11.
   PubMed Web of Science ®Google Scholar
• Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med. 2015;373(16):1490–1492. doi:10.1056/NEJMp1510079.
   PubMed Web of Science ®Google Scholar
• West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp H-G, Daniel D, McCune S, Mekhail T, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–937. doi:10.1016/S1470-2045(19)30167-6.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa1613683.
   PubMed Web of Science ®Google Scholar
• Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen J-S, Muro K, Kang WK, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2017;390(10111):2461–2471. doi:10.1016/S0140-6736(17)31827-5.
   PubMed Web of Science ®Google Scholar
• Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–351. doi:10.1056/NEJMoa1805131.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. doi:10.1056/NEJMoa1709937.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. doi:10.1056/NEJMoa1816047.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi:10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101. doi:10.2307/2533446.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed). 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.629.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (Clinical Research Ed). 2011;343:d4002. doi:10.1136/bmj.d4002.
   PubMed Web of Science ®Google Scholar
• Barlesi F, Nishio M, Cobo M, Steele N, Paramonov V, Parente B, Dear R, Berard H, Peled N, Seneviratne LC, et al. LBA54IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). Ann Oncol. 2018;29(suppl_8). doi:10.1093/annonc/mdy424.066.
   PubMedGoogle Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi:10.1056/NEJMoa1510665.
   PubMed Web of Science ®Google Scholar
• Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England). 2018;391(10122):748–757. doi:10.1016/S0140-6736(17)33297-X.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–463. doi:10.1111/j.0006-341X.2000.00455.x.
   PubMed Web of Science ®Google Scholar
• Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Aren Frontera O, Gettinger S, Holgado E, Spigel D, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29(4):959–965. doi:10.1093/annonc/mdy041.
   PubMed Web of Science ®Google Scholar
• Namikawa T, Ishida N, Tsuda S, Fujisawa K, Munekage E, Iwabu J, Munekage M, Uemura S, Tsujii S, Maeda H, et al. Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab. Surgical Case Reports. 2018;4(1):71. doi:10.1186/s40792-018-0479-3.
   PubMedGoogle Scholar
• Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users’ guide to the medical literature. JAMA. 2014;311(4):405–411. doi:10.1001/jama.2013.285063.
   PubMed Web of Science ®Google Scholar
• Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015;112(9):1421–1427. doi:10.1038/bjc.2015.124.
   PubMed Web of Science ®Google Scholar
• Passiglia F, Galvano A, Rizzo S, Incorvaia L, Listì A, Bazan V, Russo A. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: an indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int J Cancer. 2018;142(6):1277–1284. doi:10.1002/ijc.v142.6.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Paz-Ares L, Liu H, Shen K, Morehouse C, Rizvi N, Segal NH, Jin X, Zheng Y, Narwal R, et al. Prognostic significance of liver metastasis in durvalumab-treated lung cancer patients. Clin Lung Cancer. 2019;20(6):e601–e8. doi:10.1016/j.cllc.2019.06.020.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, et al. Liver metastasis and treatment outcome with Anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017;5(5):417–424. doi:10.1158/2326-6066.CIR-16-0325.
   PubMed Web of Science ®Google Scholar
• Heymann F, Tacke F. Immunology in the liver–from homeostasis to disease. Nat Rev Gastroenterol Hepatol. 2016;13(2):88–110. doi:10.1038/nrgastro.2015.200.
   PubMed Web of Science ®Google Scholar
• Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herbertson BM, Binns RM, Davies DAL. Induction of immunological tolerance by porcine liver allografts. Nature. 1969;223(5205):472–476. doi:10.1038/223472a0.
   PubMed Web of Science ®Google Scholar
• Wang J, Deng Q, Jiang YY, Zhang R, Zhu HB, Meng JX, Li, YM CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma: a case report. Oncol Lett. 2019;18(5):4415–4420. doi:10.3892/ol.2019.10783.
   PubMed Web of Science ®Google Scholar
• Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471–482. doi:10.1016/j.ccell.2019.09.006.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546. doi:10.1056/NEJMoa1910836.
   PubMed Web of Science ®Google Scholar
• Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255. doi:10.1186/s13046-019-1259-z.
   PubMed Web of Science ®Google Scholar
• Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundararaman S, D’Ambrosio D, Sharma S, Perry D, Kolker J, Davis J, et al. Stereotactic body radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® patient registry. Radiat Oncol. 2018;13(1):26. doi:10.1186/s13014-018-0969-2.
   PubMedGoogle Scholar
• Bale R, Putzer D, Schullian P. Local treatment of breast cancer liver metastasis. Cancers. 2019;11:9. doi:10.3390/cancers11091341.
   Google Scholar
• Liu X, Yao J, Song L, Zhang S, Huang T, Li Y. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J Immuno Cancer. 2019;7(1):204. doi:10.1186/s40425-019-0692-z.
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10(7):718–726. doi:10.1016/S1470-2045(09)70082-8.
   PubMed Web of Science ®Google Scholar
• Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H, Nishimura T. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 2010;70(7):2697–2706. doi:10.1158/0008-5472.CAN-09-2982.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu Y-X. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–695. doi:10.1172/JCI67313.
   PubMed Web of Science ®Google Scholar
• Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18(5):313–322. doi:10.1038/nrc.2018.6.
   PubMed Web of Science ®Google Scholar
• Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017;22(4):470–479. doi:10.1634/theoncologist.2016-0419.
   PubMed Web of Science ®Google Scholar
• Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int J Cancer. 2017;141(5):1018–1028. doi:10.1002/ijc.v141.5.
   PubMed Web of Science ®Google Scholar